Cumberland’s Phase 2 FIGHT DMD trial shows investigational oral therapy ifetroban improves cardiac function and reduces biomarkers of heart injury in Duchenne muscular dystrophy, reinforcing its potential as the first therapy targeting DMD-associated cardiomyopathy.
Written By: Meghana Jinka, PharmD
Reviewed By: Pharmacally Editorial Team
Cumberland Pharmaceuticals has reported new analyses from its Phase 2 FIGHT DMD trial, providing additional evidence that investigational oral therapy ifetroban may protect the heart in patients with Duchenne muscular dystrophy (DMD). The updated data, presented at the 2026 Parent Project Muscular Dystrophy (PPMD) Annual Conference in Orlando, further support the therapy’s potential to reduce ongoing cardiac injury while maintaining a favorable long-term safety profile.
Ifetroban Targets an Unmet Need in DMD Heart Disease
DMD is a rare inherited neuromuscular disorder caused by mutations in the dystrophin gene, leading to progressive muscle degeneration, respiratory complications, and cardiomyopathy. Although current therapies can slow skeletal muscle decline, no approved treatment specifically targets DMD-associated heart disease, which remains the leading cause of death in these patients.
Ifetroban is a once-daily oral thromboxane receptor blocker that reduces inflammation and fibrosis, two major drivers of cardiac damage. The investigational therapy has received FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations for DMD-associated cardiomyopathy.
Phase 2 Trial Demonstrates Sustained Cardiac Benefits
The 12-month Phase 2 FIGHT DMD study (NCT03340675) previously showed that high-dose ifetroban improved left ventricular ejection fraction (LVEF) by 5.4% compared with a control group consisting of placebo-treated participants and propensity score-matched natural history patients. Investigators also observed reductions in established cardiac injury biomarkers, including NT-proBNP and cardiac troponin I.
The newly presented analyses expanded these findings using additional blood biomarkers associated with heart muscle injury and tissue repair. Compared with placebo, patients receiving ifetroban experienced:
- 30% reduction in MYL3, a marker of heart muscle injury.
- 50% reduction in MYOD1, a marker associated with ongoing cellular damage.
- 2.4-fold increase in FGF16, a protein linked to cardiac protection and repair.
- 2.1-fold increase in TSPAN7, another protein involved in tissue repair mechanisms.
Together, these biomarker changes support the previously reported improvements in cardiac function and suggest that ifetroban may slow progressive heart damage in patients with DMD.
Long-term follow-up across the Phase 2 study and its ongoing open-label extension, covering up to 36 months of treatment, also demonstrated a favorable safety profile. Investigators reported no treatment-related serious adverse events and no new safety concerns during extended therapy. All participants who completed the initial 12-month trial elected to continue into the open-label extension.
Clinical Perspective and Next Steps
Presenting investigator Dr. Chet R. Villa noted that the combination of improved cardiac function and reduced biomarkers of heart muscle injury provides encouraging evidence that ifetroban may help slow DMD-related cardiomyopathy, addressing a critical therapeutic gap.
Cumberland CEO A.J. Kazimi said the new biological evidence reinforces confidence in the therapy’s ability to protect the heart beyond improvements in imaging measures.
The company plans to complete additional long-term analyses and conduct further supportive studies as it advances the clinical development of ifetroban for DMD-associated cardiomyopathy.
What This Means for Patients
Heart problems almost always develop in people with Duchenne muscular dystrophy (DMD) as they get older, and they are the main cause of death in this condition. Current medicines can help with symptoms, but none are designed to directly treat the heart damage caused by DMD.
The latest study results suggest that ifetroban may protect the heart by slowing ongoing injury and improving how well the heart works. Importantly, the medicine also looked safe over the long term, with no new serious side effects reported during up to three years of follow‑up.
It’s important to know that ifetroban is still being studied and has not yet been approved by the U.S. Food and Drug Administration (FDA) or other regulators. More research is needed to confirm these benefits. If future studies are successful, ifetroban could become the first treatment developed specifically to protect the heart in people living with DMD.
Reference
About the Writer
Meghana Jinka (LinkedIn) is a PharmD graduate with a strong interest in clinical pharmacy, clinical research, pharmacovigilance, and medical writing. She has developed expertise in evaluating scientific literature, interpreting clinical data, and communicating complex medical information in a clear and accessible manner. Through clinical training, patient counseling, and healthcare awareness activities, she has gained practical experience in evidence-based medicine and patient-centered care. Passionate about healthcare communication, Meghana is committed to developing accurate, engaging, and evidence-based healthcare documents that support healthcare professionals and the wider community.